Interferon beta
Neutralizing antibodies explain the poor clinical response to Interferon beta in a small proportion of patients with Multiple Sclerosis: a retrospective study
... Melis F, Marnetto F, Lindberg RL, Bottero R, Di Sapio A, Giordana MT: Persistent neutralizing antibodies abolish the interferon beta bioavailability in MS patients. Neurology 2003, 60:634-639. 10. Rudick ...
8
The potential teratogenic effects of interferon beta-1a and interferon beta-1b on in vitro embryonic development
... Background: Interferon beta (IFNb) was the first proven drug for the treatment of multiple sclerosis (MS). The diagnosis of MS frequently occurs in women at child- bearing age (especially in twenties and ...
7
Advances in the treatment of relapsing–remitting multiple sclerosis: the role of pegylated interferon β-1a
... IFNβ, interferon beta; M, macrophage; MMP, matrix metalloproteinase; MS, multiple sclerosis; PEG, polyethylene glycol; PEG-IFNβ, pegylated interferon β; TIMP-1, tissue inhibitor of ...
14
Renal thrombotic microangiopathy caused by interferon beta-1a treatment for multiple sclerosis
... Abstract: Interferon beta-1a is available as an immunomodulating agent for relapsing forms of multiple ...with interferon beta-1a for multiple sclerosis for 5 ...long-term interferon ...
6
Immunopharmacological consequences of immune responses to therapeutic interferon beta
... 30 et al. 1987; Lok, Lai & Leung 1990; Milella et al. 1993; Porres et al. 1989; von Wussow et al. 1988; Wussow et al. 1991). It is also reported that the percentage of NAb positive patients varies depending upon the ...
241
ExtaviJect<sup>®</sup> 30G device for subcutaneous self-injection of interferon beta-1b for multiple sclerosis: a prospective European study
... prescribed interferon beta-1b using the ExtaviJect 30G autoinjector as part of their routine clinical care were eligible to participate in the ...(including interferon beta-1b) or who were ...
10
Cycloheximide induces expression of the human interferon beta 1 gene in mouse cells transformed by bovine papillomavirus-interferon beta 1 recombinants.
... 1 0022-538X/83/070089-07$02.00/0 Copyright © 1983, American Society for Microbiology Cycloheximide Induces Expression of the Human Interferon P Gene in Mouse Cells Transformed by Bovine [r] ...
7
Low autocrine interferon beta production as a gene therapy approach for AIDS: Infusion of interferon beta engineered lymphocytes in macaques chronically infected with SIVmac251
... The persistence of 1 transduced cell per 103 circulating cells before SIV challenge was correlated with low plasma virus load and the maintenance of CD4+ and CD8+ cell counts in macaques[r] ...
11
Therapeutic efficacy of monthly subcutaneous injection of daclizumab in relapsing multiple sclerosis
... was an imbalance between treatment arms in the number of patients censored who experienced disability worsening, but left the study before disability worsening could be confirmed 12 weeks later, which was considered to ...
20
Induction or aggravation of other immune-mediated disorders by disease-modifying therapy in treatment of multiple sclerosis
... Interferon beta (IFN-β) and glatiramer acetate (GA) are the primary therapeutic immunomodulatory agents that interfere with relapsing-remitting multiple sclerosis (RRMS), and the most commonly- used drugs ...
8
Interferons and their potential in the treatment of ocular inflammation
... First results of a randomized controlled clinical trial comparing interferon beta with methotrexate for the treatment of intermediate uveitis with macular edema. Invest Ophthal[r] ...
8
<p>BetaEval Global: Prospective, Multinational, Observational Cohort Study of Patients Using BETACONNECT<sup>®</sup></p>
... The primary outcome variable was compliance with ther- apy based on the medication possession ratio (MPR). An indirect measure of compliance, MPR is bene fi cial for iden- tifying patients at risk for treatment failure ...
9
STAT1 modification improves therapeutic effects of interferons on lung cancer cells
... IFN-γ: interferon-gamma; IFN-β: interferon-beta; JAK-STAT: the Janus activated kinase-signal transducer and activator of transcription; pSTAT1: STAT1 Tyr-701 phosphorylation; FBS: fetal bovine serum; ...
10
Type I Interferon Response Limits Astrovirus Replication and Protects against Increased Barrier Permeability In Vitro and In Vivo
... Here we show that human astrovirus type 1 HAstV-1 infection induces type I interferon beta interferon [IFN-] production in differentiated Caco2 cells, which not only inhibits viral repl[r] ...
9
Interferone und Natalizumab in der Behandlung der multiplen Sklerose (MS) Interferons and Natalizumab for Multiple Sclerosis
... Interferon beta-1a und Interferon beta-1b führten im Frühstadium einer MS ...verringerte Interferon beta-1a die Progredienz, über Interferon beta-1b lässt sich ...
11
Andrographis paniculata decreases fatigue in patients with relapsing-remitting multiple sclerosis: a 12-month double-blind placebo-controlled pilot study
... Our results suggest that treatment with A. paniculata could be an effective pharmacological intervention in the mitigation of fatigue in RRMS patients treated with interferon beta. The mechanism of action ...
8
Identifying responders and nonresponders to interferon therapy in multiple sclerosis
... Abstract: Interferon beta is a well established disease-modifying agent used for relapsing-remitting multiple ...to interferon beta is strongly recommended to select patients who need a prompt ...
10
Review of daclizumab and its therapeutic potential in the treatment of relapsing–remitting multiple sclerosis
... events was similar in all the treatment groups. There were no life-threatening or opportunistic infections. The incidence of cutaneous events was higher in the daclizumab groups when compared to the interferon ...
7
The role of glatiramer acetate in the early treatment of multiple sclerosis
... Abstract: The treatment of the underlying disease process causing multiple sclerosis has continued to evolve since the initial approval of interferon-beta-1b in 1993. Current emphasis is on early treatment, ...
8
The secRNome of Listeria monocytogenes Harbors Small Noncoding RNAs That Are Potent Inducers of Beta Interferon
... ABSTRACT Cellular sensing of bacterial RNA is increasingly recognized as a deter- minant of host-pathogen interactions. The intracellular pathogen Listeria monocyto- genes induces high levels of type I interferons ...
15